A review on chitosan and its development as pulmonary particulate anti-infective and anti-cancer drug carriers

Chitosan, as a biodegradable and biocompatible polymer, is characterized by anti-microbial and anti-cancer properties. It lately has received a widespread interest for use as the pulmonary particulate backbone materials of drug carrier for the treatment of infectious disease and cancer. The success...

وصف كامل

التفاصيل البيبلوغرافية
الحاوية / القاعدة:Carbohydrate Polymers
المؤلف الرئيسي: 2-s2.0-85089817995
التنسيق: Review
اللغة:English
منشور في: Elsevier Ltd 2020
الوصول للمادة أونلاين:https://www.scopus.com/inward/record.uri?eid=2-s2.0-85089817995&doi=10.1016%2fj.carbpol.2020.116800&partnerID=40&md5=0029fd5e7e61a936786414f395bd41ec
id Rasul R.M.; Tamilarasi Muniandy M.; Zakaria Z.; Shah K.; Chee C.F.; Dabbagh A.; Rahman N.A.; Wong T.W.
spelling Rasul R.M.; Tamilarasi Muniandy M.; Zakaria Z.; Shah K.; Chee C.F.; Dabbagh A.; Rahman N.A.; Wong T.W.
2-s2.0-85089817995
A review on chitosan and its development as pulmonary particulate anti-infective and anti-cancer drug carriers
2020
Carbohydrate Polymers
250

10.1016/j.carbpol.2020.116800
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85089817995&doi=10.1016%2fj.carbpol.2020.116800&partnerID=40&md5=0029fd5e7e61a936786414f395bd41ec
Chitosan, as a biodegradable and biocompatible polymer, is characterized by anti-microbial and anti-cancer properties. It lately has received a widespread interest for use as the pulmonary particulate backbone materials of drug carrier for the treatment of infectious disease and cancer. The success of chitosan as pulmonary particulate drug carrier is a critical interplay of their mucoadhesive, permeation enhancement and site/cell-specific attributes. In the case of nanocarriers, various microencapsulation and micro-nano blending systems have been devised to equip them with an appropriate aerodynamic character to enable efficient pulmonary aerosolization and inhalation. The late COVID-19 infection is met with acute respiratory distress syndrome and cancer. Chitosan and its derivatives are found useful in combating HCoV and cancer as a function of their molecular weight, substituent type and its degree of substitution. The interest in chitosan is expected to rise in the next decade from the perspectives of drug delivery in combination with its therapeutic performance. © 2020 Elsevier Ltd
Elsevier Ltd
1448617
English
Review
All Open Access; Green Open Access
author 2-s2.0-85089817995
spellingShingle 2-s2.0-85089817995
A review on chitosan and its development as pulmonary particulate anti-infective and anti-cancer drug carriers
author_facet 2-s2.0-85089817995
author_sort 2-s2.0-85089817995
title A review on chitosan and its development as pulmonary particulate anti-infective and anti-cancer drug carriers
title_short A review on chitosan and its development as pulmonary particulate anti-infective and anti-cancer drug carriers
title_full A review on chitosan and its development as pulmonary particulate anti-infective and anti-cancer drug carriers
title_fullStr A review on chitosan and its development as pulmonary particulate anti-infective and anti-cancer drug carriers
title_full_unstemmed A review on chitosan and its development as pulmonary particulate anti-infective and anti-cancer drug carriers
title_sort A review on chitosan and its development as pulmonary particulate anti-infective and anti-cancer drug carriers
publishDate 2020
container_title Carbohydrate Polymers
container_volume 250
container_issue
doi_str_mv 10.1016/j.carbpol.2020.116800
url https://www.scopus.com/inward/record.uri?eid=2-s2.0-85089817995&doi=10.1016%2fj.carbpol.2020.116800&partnerID=40&md5=0029fd5e7e61a936786414f395bd41ec
description Chitosan, as a biodegradable and biocompatible polymer, is characterized by anti-microbial and anti-cancer properties. It lately has received a widespread interest for use as the pulmonary particulate backbone materials of drug carrier for the treatment of infectious disease and cancer. The success of chitosan as pulmonary particulate drug carrier is a critical interplay of their mucoadhesive, permeation enhancement and site/cell-specific attributes. In the case of nanocarriers, various microencapsulation and micro-nano blending systems have been devised to equip them with an appropriate aerodynamic character to enable efficient pulmonary aerosolization and inhalation. The late COVID-19 infection is met with acute respiratory distress syndrome and cancer. Chitosan and its derivatives are found useful in combating HCoV and cancer as a function of their molecular weight, substituent type and its degree of substitution. The interest in chitosan is expected to rise in the next decade from the perspectives of drug delivery in combination with its therapeutic performance. © 2020 Elsevier Ltd
publisher Elsevier Ltd
issn 1448617
language English
format Review
accesstype All Open Access; Green Open Access
record_format scopus
collection Scopus
_version_ 1828987871486279680